1.28
Schlusskurs vom Vortag:
$1.35
Offen:
$1.32
24-Stunden-Volumen:
1.24M
Relative Volume:
0.55
Marktkapitalisierung:
$146.68M
Einnahmen:
$13.45M
Nettoeinkommen (Verlust:
$-178.23M
KGV:
-0.7758
EPS:
-1.65
Netto-Cashflow:
$-132.53M
1W Leistung:
+15.32%
1M Leistung:
+41.80%
6M Leistung:
-51.70%
1J Leistung:
-66.93%
Fate Therapeutics Inc Stock (FATE) Company Profile
Firmenname
Fate Therapeutics Inc
Sektor
Branche
Telefon
858.875.1803
Adresse
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Vergleichen Sie FATE mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
FATE
Fate Therapeutics Inc
|
1.28 | 146.68M | 13.45M | -178.23M | -132.53M | -1.65 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-11-18 | Hochstufung | BofA Securities | Underperform → Neutral |
2024-06-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
2023-01-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
2023-01-06 | Herabstufung | Cowen | Outperform → Market Perform |
2023-01-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
2023-01-06 | Herabstufung | Stifel | Buy → Hold |
2023-01-06 | Herabstufung | Truist | Buy → Hold |
2023-01-06 | Herabstufung | Wedbush | Outperform → Neutral |
2023-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
2022-12-22 | Herabstufung | Oppenheimer | Outperform → Perform |
2022-12-15 | Eingeleitet | Goldman | Sell |
2022-11-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
2022-07-28 | Eingeleitet | Needham | Hold |
2022-07-11 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
2022-02-11 | Fortgesetzt | BMO Capital Markets | Market Perform |
2021-12-15 | Hochstufung | Wedbush | Neutral → Outperform |
2021-12-07 | Eingeleitet | Cowen | Outperform |
2021-11-09 | Hochstufung | Citigroup | Neutral → Buy |
2021-08-26 | Eingeleitet | Morgan Stanley | Equal-Weight |
2021-06-07 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2021-05-07 | Hochstufung | Wedbush | Neutral → Outperform |
2021-04-26 | Fortgesetzt | Jefferies | Buy |
2021-02-26 | Eingeleitet | BofA Securities | Buy |
2021-02-26 | Herabstufung | Wedbush | Outperform → Neutral |
2021-02-11 | Herabstufung | Citigroup | Buy → Neutral |
2021-01-27 | Fortgesetzt | H.C. Wainwright | Neutral |
2020-05-13 | Eingeleitet | H.C. Wainwright | Buy |
2020-03-04 | Eingeleitet | Barclays | Overweight |
2020-01-09 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2019-12-30 | Bestätigt | Mizuho | Buy |
2019-12-09 | Hochstufung | Wells Fargo | Market Perform → Outperform |
2019-11-12 | Eingeleitet | SunTrust | Buy |
2019-11-06 | Herabstufung | Wells Fargo | Outperform → Market Perform |
2019-10-01 | Eingeleitet | Stifel | Buy |
2019-08-09 | Eingeleitet | BTIG Research | Buy |
2019-07-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
2019-07-12 | Eingeleitet | Oppenheimer | Outperform |
2019-06-13 | Eingeleitet | Mizuho | Buy |
2019-06-07 | Eingeleitet | ROTH Capital | Neutral |
2019-05-31 | Eingeleitet | Guggenheim | Buy |
2019-05-24 | Fortgesetzt | Citigroup | Buy |
2019-03-28 | Eingeleitet | SVB Leerink | Outperform |
2019-01-03 | Herabstufung | Stephens | Overweight → Equal-Weight |
2018-11-05 | Eingeleitet | Jefferies | Buy |
2018-08-01 | Eingeleitet | Citigroup | Buy |
2018-03-06 | Herabstufung | H.C. Wainwright | Buy → Neutral |
Alle ansehen
Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten
Geode Capital Management LLC Sells 31,279 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Recent uptick might appease Fate Therapeutics, Inc. (NASDAQ:FATE) institutional owners after losing 66% over the past year - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
Russell Investments Group Ltd. Increases Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
FATE Shares Experience Decline in Value - knoxdaily.com
Analyzing Ratios: Fate Therapeutics Inc (FATE)’s Financial Story Unveiled - DWinneX
Ratios Revealed: Decoding Allarity Therapeutics Inc (ALLR)’s Financial Health - DWinneX
JPMorgan Chase & Co. Reduces Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics Inc [FATE] Stock trading around $1.25 per share: What’s Next? - dbtnews.com
Nothing is Better Than Fate Therapeutics Inc (FATE) stock at the moment - Sete News
Is Fate Therapeutics Inc (NASDAQ:FATE) stock a better investment at this time? - uspostnews.com
The Attractiveness of Investing In Fate Therapeutics Inc (FATE) is Growing - knoxdaily.com
Franklin Resources Inc. Has $273,000 Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Vanguard Group Inc. Cuts Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag - MSN
Fate Therapeutics gets RMAT status from FDA for Lupus treatment - MSN
Fate Therapeutics’ iPSC-derived CAR-T FT819 Nabs FDA RMAT Designation for Lupus - CGTLive®
Fate Therapeutics’ new CAR T-cell therapy fast-tracked by FDA - Investing.com South Africa
Fate Therapeutics receives RMAT designation from FDA for FT819 - TipRanks
Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic - MSN
Fate Therapeutics gets RMAT status from FDA for lupus treatment - Seeking Alpha
Fate Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy Designation for Lupus Cell Therapy; Shares Fall - marketscreener.com
Fate Therapeutics, Inc. Receives Regenerative Medicine Advanced Therapy Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus - marketscreener.com
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE) - GlobeNewswire
American Century Companies Inc. Buys 12,295 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
NK Cells Market Hits New High | Major Giants NantKwest, Fate Therapeutics, Affimed, Glycostem, Nkarta - openPR.com
Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by Prudential Financial Inc. - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Recommendation of “Hold” from Analysts - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Stock Position Decreased by Thrivent Financial for Lutherans - Defense World
Fate Therapeutics (FATE) Down 34.6% Since Last Earnings Report: Can It Rebound? - MSN
Fate Therapeutics (NASDAQ:FATE) Stock Crosses Below 200 Day Moving Average – Here’s What Happened - Defense World
Fate Therapeutics Inc [FATE] Former Officer and Director makes an insider purchase of 113,178 shares worth 0.1 million. – Knox Daily - knoxdaily.com
FATE CLASS ACTION: Hagens Berman Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Lawsuit Pending - ACCESS Newswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Fate Therap stock hits 52-week low at $0.87 amid sharp decline - Investing.com
FY2025 EPS Forecast for Fate Therapeutics Raised by Analyst - The AM Reporter
Equities Analysts Issue Forecasts for FATE FY2025 Earnings - Defense World
Weekly Research Analysts’ Ratings Updates for Fate Therapeutics (FATE) - Defense World
Fate Therapeutics Inc. Faces Global Expansion Challenges Amid Political and Economic Uncertainties - MSN
Fate Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com South Africa
Fate Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com
Fate Therapeutics at Leerink Conference: Strategic Shift to FT-819 By Investing.com - Investing.com UK
Fate Therapeutics at Barclays Conference: Strategic Shift to Autoimmune Focus - Investing.com UK
FATE Stock Plummets to 52-Week Low at $0.87 Amidst Sharp Decline - Investing.com
Fate Therapeutics (NASDAQ:FATE) Rating Lowered to “Sell” at StockNews.com - Defense World
Fate Therapeutics price target lowered to $2.50 from $3 at BofA - TipRanks
Q1 EPS Estimates for Fate Therapeutics Boosted by Wedbush - Defense World
Fate Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Finanzdaten der Fate Therapeutics Inc-Aktie (FATE)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):